# Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis

> **NCT00275613** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 10 (actual)

## Conditions studied

- Glomerulonephritis, Membranoproliferative

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00275613
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2013-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275613, "Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00275613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*